Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Apotea AB (publ)CHIX:APOTES 18 EV-to-OCF is 33.51 as of Aug. 25, 2026, which is 15% above its 10-year median of 29.11. GuruFocus rates CHIX:APOTES with a GF Score™ of 18/100. The stock has 1 warning sign investors should review. Among 684 Healthcare Providers & Services companies, Apotea AB (publ) ranks worse than 87.72% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Apotea AB (publ)'s Enterprise Value is kr7,841 Mil.
Apotea AB (publ)'s Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was kr234 Mil. Therefore, Apotea AB (publ)'s EV-to-OCF for today is 33.51.
The historical rank and industry rank for Apotea AB (publ)'s EV-to-OCF or its related term are showing as below:
CHIX:APOTEs'
s EV-to-OCF Range Over the Past 10 Years
Min: 18.71 Med: 29.11 Max: 44.89
Current: 33.8
During the past 5 years, the highest EV-to-OCF of Apotea AB (publ) was 44.89. The lowest was 18.71. And the median was 29.11.
CHIX:APOTEs's EV-to-OCF is ranked worse than 87.72% of 684
companies
in the Healthcare Providers & Services industry
Industry Median: 8.885
vs CHIX:APOTEs: 33.80
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Apotea AB (publ) (CHIX:APOTEs) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Apotea AB (publ)'s PE Ratio (TTM) for today is calculated as:
Apotea AB (publ)'s share price for today is kr65.20.
Apotea AB (publ)'s Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr2.360.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Apotea AB (publ) EV-to-OCF Related Terms
Apotea AB (publ) EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Apotea AB (publ)'s EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Apotea AB (publ)'s EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apotea AB (publ) EV-to-OCF vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Apotea AB (publ)'s EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Apotea AB (publ)'s EV-to-OCF falls into.
Apotea AB (publ)'s current Enterprise Value is kr7,841 Mil.
Apotea AB (publ)'s Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr234 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apotea AB (publ) (CHIX:APOTES) has a EV-to-OCF of 33.51 as of Aug. 25, 2026. This is 15% above median its historical median of 29.11. Over the past decade, Apotea AB (publ)'s EV-to-OCF has ranged from 18.71 to 44.89. According to the industry distribution chart, Apotea AB (publ) ranks #600 out of 684 companies in the Healthcare Providers & Services industry, placing it in the top 87.7%.
Is Apotea AB (publ)'s EV-to-OCF too high?
Apotea AB (publ)'s current EV-to-OCF of 33.51 is 15% above median its 10-year median of 29.11. Over the past 10 years, this metric has ranged from a low of 18.71 to a high of 44.89. The Healthcare Providers & Services industry median EV-to-OCF is 8.89. Apotea AB (publ)'s value of 33.51 is 277.2% above this industry median. Based on the distribution chart, Apotea AB (publ) ranks #600 out of 684 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Apotea AB (publ) has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Apotea AB (publ)'s EV-to-OCF compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Apotea AB (publ) ranks #600 out of 684 companies for EV-to-OCF. This places Apotea AB (publ) in the lower half of its industry. The industry median EV-to-OCF is 8.89. Apotea AB (publ)'s value of 33.51 is 277.2% above this benchmark. Historically, Apotea AB (publ)'s own EV-to-OCF has ranged from 18.71 to 44.89 over the past decade. While the company's 10-year median is 29.11 vs. the industry median of 8.89, Apotea AB (publ) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Healthcare Providers & Services company?
The median EV-to-OCF among Healthcare Providers & Services companies is 8.89, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Apotea AB (publ)'s current EV-to-OCF of 33.51 is 277.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median EV-to-OCF is 8.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apotea AB (publ)'s current EV-to-OCF is 33.51, which is 15% above median its own 10-year median of 29.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apotea AB (publ) stock overvalued right now?
Apotea AB (publ) (CHIX:APOTES) has a current EV-to-OCF of 33.51. The current EV-to-OCF is 33.51, which is 15% above median its 10-year median of 29.11 and 277.2% above the Healthcare Providers & Services industry median of 8.89. Apotea AB (publ)'s overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Apotea AB (publ) (CHIX:APOTES), the current EV-to-OCF is 33.51 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Apotea AB (publ) is engaged in the online pharmacy with fast deliveries, good prices and a large selection. Its vision is to be tomorrow's pharmacy by constantly facilitating and simplifying for the customer.
18GF Score
Get the complete analysis for CHIX:APOTES
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:APOTES has been successfully added to your 
